Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer’s Disease (AD)

Journal of the American Geriatrics Society

Fecha de publicación: 31 de diciembre de 2021

Autores: Esther S. Oh MD, PhDPaul B. Rosenberg MDGail B. Rattinger PharmD, PhDElizabeth A. Stuart PhDConstantine G. Lyketsos MD, MHSJeannie‐Marie S. Leoutsakos PhD, MHS


Background: There are growing concerns about the safety and efficacy of psychotropic medications in Alzheimer’s disease (AD). We sought to examine associations between psychotropic medication exposure and longitudinal change in cognitive, functional, and neuropsychiatric outcomes in a large clinical AD cohort.

Enviar comentario